• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol. Comparison of SARS-CoV-2 Detection from Nasopharyngeal Swab Samples by the Roche cobas? 6800 SARS-CoV-2 Test and a Laboratory-Developed

tetano

Editor, Senior Moderator
J Med Virol. 2020 May 8. doi: 10.1002/jmv.25988. [Epub ahead of print]
Comparison of SARS-CoV-2 Detection from Nasopharyngeal Swab Samples by the Roche cobas? 6800 SARS-CoV-2 Test and a Laboratory-Developed Real-Time RT-PCR test.


Pujadas E[SUP]1[/SUP], Ibeh N[SUP]1[/SUP], Hernandez MM[SUP]2,[/SUP][SUP]3[/SUP], Waluszko A[SUP]4[/SUP], Sidorenko T[SUP]4[/SUP], Flores V[SUP]5[/SUP], Shiffrin B[SUP]5[/SUP], Chiu N[SUP]5[/SUP], Young-Francois A[SUP]5[/SUP], Nowak MD[SUP]1[/SUP], Paniz-Mondolfi AE[SUP]1[/SUP], Sordillo EM[SUP]1[/SUP], Cordon-Cardo C[SUP]1[/SUP], Houldsworth J[SUP]1[/SUP], Gitman MR[SUP]1[/SUP].

Author information




Abstract

The urgent need to implement and rapidly expand testing for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection has led to development of multiple assays. How these tests perform relative to one another is poorly understood. We evaluated the concordance between the Roche Diagnostics cobas? 6800 SARS-CoV-2 Test and a laboratory- developed Real-Time RT-PCR test (LDT) based on a modified Centers for Disease Control and Prevention (CDC) protocol, for the detection of SARS-CoV-2 in samples submitted to the Clinical Laboratories of the Mount Sinai Health System. 1006 Nasopharyngeal swabs in universal transport medium from persons under investigation were tested for SARS-CoV-2 as part of routine clinical care using the cobas SARS-CoV2 test with subsequent evaluation by the LDT. Cycle threshold values were analyzed and interpreted as either positive ('Detected' or 'Presumptive Positive'), negative ('Not Detected'), inconclusive, or invalid. Statistical analysis was performed using GraphPad Prism 8. The cobas SARS-CoV2 test reported 706 positives and 300 negatives. The LDT reported 640 positives, 323 negatives, 34 inconclusive, and 9 invalids. When excluding inconclusive and invalid results, the overall percent agreement between the two platforms was 95.8%. Cohen's kappa coefficient (κ) was 0.904 (95 % CI 0.875-0.933), suggesting almost perfect agreement between both platforms. An overall discordance rate of 4.2% between the two systems may reflect differences in primer sequences, assay limit of detection, or other factors, highlighting the importance of comparing the performance of different testing platforms. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.



KEYWORDS:

RNA extraction; SARS; coronavirus


PMID:32383179DOI:10.1002/jmv.25988
 
Back
Top